Colon cancer is the second leading cause of mortality of cancer worldwide1 .The 5-fluorouracil (5-FU) is an important option as adjuvant chemotherapy for colon cancer at stages II, III and IV alone or in combination with other anti-cancer drugs2. However, its short half-life, low response rates and the emergence of resistance demands the discovery of novel therapeutic strategies3.